Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19

 Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19

Sorrento Collaborates with Mount Sinai to Develop Ab Combination for Neutralizing SARS-CoV-2 and other Emerging Variants of COVID-19

Shots:

  • The companies signed an exclusive license agreement to develop COVISHIELD + two mAb cocktail against emerging variants of SARS-CoV-2 including UK (B.1.1.7), South Africa (B.1.351), and Japan/Brazil (B.1.128) variants
  • The pre-clinical development of Ab combination (IV and intranasal) including Sorrento and Mount Sinai Abs is underway
  • The collaboration follows Sorrento’s efforts to eradicate COVID-19 which includes STI-2020 (COVI-AMG) and STI-2099 (COVIDROPS). The license contemplates Sorrento and Mount Sinai pursuing future collaborations in developing humanized mAb for therapeutic applications

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post